Published in Nat Cell Biol on January 13, 2008
Aberrant Expression of Micro RNA for Diagnosis of Breast Cancer | NCT04720508
Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51
The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem (2008) 10.08
MicroRNAs and cancer: short RNAs go a long way. Cell (2009) 7.25
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67
miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res (2008) 6.30
MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol (2009) 5.92
MicroRNAs--the micro steering wheel of tumour metastases. Nat Rev Cancer (2009) 5.47
Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer (2011) 5.12
miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol (2008) 4.81
Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol (2010) 4.80
MicroRNA functions in stress responses. Mol Cell (2010) 4.46
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal (2010) 4.15
MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer (2011) 3.91
Phosphorylation of the human microRNA-generating complex mediates MAPK/Erk signaling. Cell (2009) 3.90
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med (2011) 3.82
Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One (2010) 3.50
MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov (2013) 3.33
MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet (2010) 3.12
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A (2008) 3.08
miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep (2009) 3.03
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol (2008) 3.02
microRNA involvement in human cancer. Carcinogenesis (2012) 2.98
miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One (2009) 2.97
Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci U S A (2010) 2.91
What would you do if you could sequence everything? Nat Biotechnol (2008) 2.89
MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem (2010) 2.85
MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res (2010) 2.83
A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One (2010) 2.64
MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res (2009) 2.59
Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res (2009) 2.58
The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol (2009) 2.56
Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell (2012) 2.50
MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. J Biol Chem (2010) 2.49
Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res (2009) 2.45
Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol (2008) 2.30
LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med (2012) 2.24
Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener (2012) 2.11
Characterization of the Melanoma miRNAome by Deep Sequencing. PLoS One (2010) 2.08
MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med (2008) 1.99
KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol (2009) 1.97
Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol (2010) 1.92
MicroRNA miR-378 regulates nephronectin expression modulating osteoblast differentiation by targeting GalNT-7. PLoS One (2009) 1.88
Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer. Br J Cancer (2010) 1.86
Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell (2010) 1.86
MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev (2011) 1.85
NAViGaTing the micronome--using multiple microRNA prediction databases to identify signalling pathway-associated microRNAs. PLoS One (2011) 1.80
Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis. Nat Commun (2011) 1.80
miRNA control of tumor cell invasion and metastasis. Int J Cancer (2010) 1.79
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77
Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol (2009) 1.75
MiR-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle (2012) 1.74
MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett (2012) 1.73
Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol (2013) 1.73
Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One (2011) 1.72
Breast cancer metastasis: a microRNA story. Breast Cancer Res (2008) 1.70
Methylation of an intronic region regulates miR-199a in testicular tumor malignancy. Oncogene (2011) 1.64
Analysis of CDS-located miRNA target sites suggests that they can effectively inhibit translation. Genome Res (2013) 1.59
MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis (2012) 1.55
Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma. BMC Cancer (2010) 1.55
Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One (2011) 1.55
Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta (2014) 1.53
Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer (2009) 1.51
MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer. PLoS One (2011) 1.51
Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res (2012) 1.50
Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA (2009) 1.48
Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res (2010) 1.48
Modeling metastasis in the mouse. Curr Opin Pharmacol (2010) 1.46
miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer (2011) 1.44
Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. Int J Cancer (2009) 1.42
miR-10b targets Tiam1: implications for Rac activation and carcinoma migration. J Biol Chem (2010) 1.41
The expression profile of C19MC microRNAs in primary human trophoblast cells and exosomes. Mol Hum Reprod (2012) 1.41
MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11. Oncotarget (2012) 1.40
Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res (2010) 1.40
The clinical potential of microRNAs. J Hematol Oncol (2010) 1.39
Ratio of miR-196s to HOXC8 messenger RNA correlates with breast cancer cell migration and metastasis. Cancer Res (2010) 1.39
Novel functions for small RNA molecules. Curr Opin Mol Ther (2009) 1.39
Retracted Glabridin attenuates the migratory and invasive capacity of breast cancer cells by activating microRNA-200c. Cancer Sci (2014) 1.39
Tissue elasticity regulated tumor gene expression: implication for diagnostic biomarkers of primitive neuroectodermal tumor. PLoS One (2015) 1.38
Noncanonical TGF-β signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia (2011) 1.38
Prioritization of disease microRNAs through a human phenome-microRNAome network. BMC Syst Biol (2010) 1.37
Parallel DNA pyrosequencing unveils new zebrafish microRNAs. BMC Genomics (2009) 1.36
MicroRNA control of epithelial-mesenchymal transition and metastasis. Cancer Metastasis Rev (2012) 1.34
MicroRNAs can regulate human APP levels. Mol Neurodegener (2008) 1.34
microRNA control of cell-cell signaling during development and disease. Cell Cycle (2008) 1.32
microRNA, cell cycle, and human breast cancer. Am J Pathol (2010) 1.32
microRNA and cancer. AAPS J (2010) 1.32
Rheostatic signaling by CD44 and hyaluronan. Cell Signal (2009) 1.30
miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res (2010) 1.29
Non-coding RNAs: a key to future personalized molecular therapy? Genome Med (2010) 1.29
miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF-κB factor in human fibrosarcoma cells. J Cell Physiol (2012) 1.29
Identification of miR-21 targets in breast cancer cells using a quantitative proteomic approach. Proteomics (2009) 1.28
microRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin. J Biol Chem (2010) 1.27
MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PLoS One (2013) 1.27
The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One (2012) 1.26
MicroRNAs as biomarkers in colorectal cancer. Am J Pathol (2010) 1.25
Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression. Breast Cancer Res (2010) 1.24
Functional screening for miRNAs targeting Smad4 identified miR-199a as a negative regulator of TGF-β signalling pathway. Nucleic Acids Res (2012) 1.24
The role of microRNAs in breast cancer migration, invasion and metastasis. Int J Mol Sci (2012) 1.24
MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem (2010) 1.23
A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Long noncoding RNAs with enhancer-like function in human cells. Cell (2010) 13.00
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Cancer immunotherapy comes of age. Nature (2011) 12.35
A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell (2006) 11.01
A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67
microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A (2006) 8.24
Genomewide association study of leprosy. N Engl J Med (2009) 8.17
Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 7.88
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature (2003) 7.69
RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. Cell (2007) 7.06
Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell (2011) 6.80
Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci U S A (2008) 6.59
Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J (2007) 6.26
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst (2008) 6.13
Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet (2003) 5.51
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA (2004) 4.88
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
miR-148 targets human DNMT3b protein coding region. RNA (2008) 4.56
Modulation of the antitumor immune response by complement. Nat Immunol (2008) 4.53
Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep (2003) 4.52
PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A (2003) 4.46
The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev (2009) 4.15
Resolution of lung inflammation by CD44. Science (2002) 4.09
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature (2011) 4.07
miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther (2007) 3.93
MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer (2011) 3.91
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol (2005) 3.88
Laser-capture microdissection. Nat Protoc (2006) 3.80
eRNAs are required for p53-dependent enhancer activity and gene transcription. Mol Cell (2012) 3.63
Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet (2009) 3.59
The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res (2003) 3.58
Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med (2004) 3.55
Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists. J Cutan Pathol (2004) 3.43
The TLR4 gene polymorphisms and susceptibility to cancer: a systematic review and meta-analysis. Eur J Cancer (2012) 3.41
Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One (2010) 3.38
A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell (2005) 3.35
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med (2008) 3.35
Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ Res (2005) 3.34
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res (2013) 3.27
RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overload-induced Ca2+ release (SOICR). Proc Natl Acad Sci U S A (2004) 3.25
Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res (2008) 3.06
Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes (2005) 3.04
Expanding window compressed sensing for non-uniform compressible signals. Sensors (Basel) (2012) 2.98
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol (2008) 2.82
Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest (2008) 2.73
The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. Hum Mol Genet (2003) 2.73
Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J (2003) 2.70
Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord (2007) 2.68
PUMA regulates intestinal progenitor cell radiosensitivity and gastrointestinal syndrome. Cell Stem Cell (2008) 2.68
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene (2004) 2.67
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol (2011) 2.67
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest (2009) 2.66
Enhanced basal activity of a cardiac Ca2+ release channel (ryanodine receptor) mutant associated with ventricular tachycardia and sudden death. Circ Res (2002) 2.64
Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol (2010) 2.63
A Pumilio-induced RNA structure switch in p27-3' UTR controls miR-221 and miR-222 accessibility. Nat Cell Biol (2010) 2.53
Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest (2010) 2.48
Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res (2007) 2.45
An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol (2004) 2.45
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 2.43
Evolution of sleep quantity, sleep deprivation, mood disturbances, empathy, and burnout among interns. Acad Med (2006) 2.39
Alternative cleavage and polyadenylation: extent, regulation and function. Nat Rev Genet (2013) 2.37
MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res (2008) 2.35